Share Price:

APNASPENAspen Pharmacare Hldgs13411-89 (-0.66%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Renewal of Cautionary Announcement

APN – Aspen Pharmacare Holdings Limited – Trading statement Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN & ISIN: ZAE000066692 (“Aspen”) Renewal of Cautionary Announcement Shareholders are referred to the renewal cautionary announcement released by Aspen on 7 March 2013 in which shareholders were advised of… Continue reading Renewal of Cautionary Announcement

Aspen to invest more than R1,9 billion in infant nutritional deal with Pfizer

Shareholders of Aspen Holdings are advised that Aspen Group companies (“Aspen”) have concluded agreements with Nestlé S.A. in respect of the acquisition of certain rights to intellectual property licenses, net assets and shares in the IN businesses presently conducted by Pfizer which distribute a portfolio of IN products in Australia (the “Australian IN business”) and… Continue reading Aspen to invest more than R1,9 billion in infant nutritional deal with Pfizer

Aspen increases revenue to R9 billion

JSE Limited listed Aspen Pharmacare Holdings Limited (Apn), the ninth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the interim period ended 31 December 2012. Group Performance Revenue from continuing operations increased by 20% to R9.0 billion. Operating profit from continuing operations rose by 24% to R2.5… Continue reading Aspen increases revenue to R9 billion

Renewal of Cautionary Announcement

Shareholders are referred to the cautionary announcement released by Aspen on 4 February 2013 (and subsequent renewals of this cautionary announcement) in which shareholders were advised of discussions between Aspen and MSD, known as Merck in the United States and Canada, in respect of a possible transaction comprising the acquisition of an active pharmaceutical ingredient… Continue reading Renewal of Cautionary Announcement

Aspen Trading Statement

APN – Aspen Pharmacare Holdings Limited – Trading statement Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN & ISIN: ZAE000066692 (“Aspen”) Trading statement Aspen shareholders are hereby advised that, diluted normalised headline earnings per share (“DNHEPS”) from continuing operations, headline earnings per share and earnings per… Continue reading Aspen Trading Statement

Cautionary Announcement – Discussions with MSD

ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) Registration number 1985/0002935/06 Share code: APN ISIN: ZAE000066692 (“Aspen” or “the Company”) CAUTIONARY ANNOUNCEMENT – DISCUSSIONS WITH MSD Shareholders are advised that Aspen is currently engaged in discussions with MSD (known as Merck in the United States and Canada) in respect of a possible… Continue reading Cautionary Announcement – Discussions with MSD

Stephen Saad named as Business Leader of the Year

STEPHEN SAAD AWARDED BUSINESS LEADER OF THE YEAR TITLE Johannesburg: Aspen Group Chief Executive, Stephen Saad, was named as the Business Leader of the Year at the annual Sunday Times Top 100 Companies banquet last night. Durban-based Stephen, who graduated from the University of Natal in 1986 with a B.Com and later qualified as a… Continue reading Stephen Saad named as Business Leader of the Year

Aspen’s revenue increases by 23%

JSE Ltd listed Aspen Pharmacare Holdings Limited (APN), Africa’s largest pharmaceutical manufacturer, has announced pleasing results for the year ended 30 June 2012, extending its record of growth for a fourteenth consecutive year. Group Performance Revenue from continuing operations rose by 23 percent to R15.3 billion. Operating profit from continuing operations increased by 25 percent… Continue reading Aspen’s revenue increases by 23%

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: